Soligenix, a biopharmaceutical company, has commenced a next generation anthrax vaccine development project under the agreement with Harvard University.
The company entered a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein.
The initial phase of the program is in line with $9.4m National Institute of Allergy and Infectious Disease (NIAID) grant to develop thermo-stable ricin and anthrax vaccines.
Soligenix hopes to develop Collier anthrax vaccine with an efficacy profile superior to other anthrax vaccines.
The vaccine currently in use, known as AVA (anthrax vaccine adsorbed), consists of a defined, but impure, mixture of bacterial components, the company said.